FDA Approves GalafoldTM (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease
(World News Science)

First Precision and First Oral Medicine for Fabry Disease Approved for 348 Amenable GLA Variants Galafold is the First New Treatment Option for Fabry Disease in the U.S. in 15+ Years Amicus Therapeutics to Host Conference Call on August 13 at 8 a.m. ET CRANBURY, N.J., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of GalafoldTM (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. Galafold was approved...